CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Carboplatin, Pemetrexed and Bevacizumabdrug
Likely dose
Carboplatin, Pemetrexed and Bevacizumab 500 mg/M2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00614822
NCT00614822Phase 2Completed
CompareCT.gov

A Phase II Trial of Carboplatin, Bevacizumab and Pemetrexed in Advanced Non-Small Cell Lung Cancer

Christiana Care Health Services·interventional·Posted Feb 13, 2008·Updated Mar 20, 2019

In Brief

A Phase 2 clinical trial evaluating Carboplatin, Pemetrexed and Bevacizumab for Non Small Cell Lung Cancer. Completed, enrolled 50 participants.

Detailed Summary

The purpose of this study is to look for an improvement in progression free survival with the combination of bevacizumab, carboplatin and pemetrexed in patients with newly diagnosed advanced/metastatic non small cell lung cancer. Overall survival and safety will also be assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
Countries--
CollaboratorsEli Lilly and Company

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2008
Enrollment StartNov 1, 2007
Primary CompletionAug 22, 2016
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 18.4 years ago

Interventions

Carboplatin, Pemetrexed and Bevacizumabdrug

Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles